CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Angiotensin Receptor BlockersWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D012120 Respiration Disorders NIH 0.29
D012140 Respiratory Tract Diseases NIH 0.24

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease

The Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY) study is a pragmatic prospective, open-label, randomised controlled trial. CLARITY aims to examine the effectiveness of angiotensin II receptor blockers (ARBs) on improving the outcomes of people who tested positive for COVID-19 disease.

NCT04394117 SARS-Cov-2 COVID-19 Drug: Angiotensin Receptor Blockers
MeSH:Respiration Disorders Respiratory Tract Diseases

Primary Outcomes

Description: To determine whether the addition of the intervention, compared to standard care, changes the clinical health score of a participant on the following scale; Not hospitalized, no limitations on activities. Not hospitalized, limitation on activities; Hospitalized, not requiring supplemental oxygen; Hospitalized, requiring supplemental oxygen; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); Death;

Measure: 7-Point National Institute of Health Clinical Health Score

Time: 28 Days

Secondary Outcomes

Description: To determine whether the addition of the intervention, compared to standard care, changes the clinical health score of a participant on the following scale; Not hospitalized, no limitations on activities. Not hospitalized, limitation on activities; Hospitalized, not requiring supplemental oxygen; Hospitalized, requiring supplemental oxygen; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); Death;

Measure: 7-Point National Institute of Health Clinical Health Score

Time: 15 Days

Description: To determine whether the addition of the intervention, compared to standard care, changes the risk of all cause mortality

Measure: Mortality

Time: 28 Days

Description: To determine whether the addition of the intervention, compared to standard care, changes the risk of all cause mortality

Measure: Mortality

Time: 90 Days

Description: To determine whether the addition of the intervention, compared to standard care, changes the count of all cause Intensive Care Unit admission

Measure: Intensive Care Unit Admission

Time: 28 Days

Description: To determine whether the addition of the intervention, compared to standard care, changes the count of all cause Intensive Care Unit admission

Measure: Intensive Care Unit Admission

Time: 90 Days

Description: To determine whether the addition of the intervention, compared to standard care, changes the number of days total, of intensive care unit admission

Measure: Intensive Care Unit Admission

Time: 90 Days

Description: To determine whether the addition of the intervention, compared to standard care, changes the incidence of respiratory failure

Measure: Respiratory Failure

Time: 90 Days

Description: To determine whether the addition of the intervention, compared to standard care, changes the requirements for dialysis

Measure: Dialysis Requirement

Time: 90 Days

Description: To determine whether the addition of the intervention, compared to standard care, changes the number of hospitalisation days

Measure: Hospitalisation Days

Time: 28 Days

Description: To determine whether the addition of the intervention, compared to standard care, changes the number of hospitalisation days

Measure: Hospitalisation Days

Time: 90 Days

Description: To determine whether the addition of the intervention, compared to standard care, changes need for ventilation

Measure: Ventilator-Free Days

Time: 28 Days

Description: To determine whether the addition of the intervention, compared to standard care, changes need for dialysis

Measure: Dialysis Days

Time: 28 Days

Description: To determine whether the addition of the intervention, compared to standard care, changes risk of acute kidney injury, based on the idney Disease: Improving Global Outcomes definition

Measure: Acute Kidney Injury

Time: 28 Days

Description: To determine whether the addition of the intervention, compared to standard care, changes risk of hypotension requiring vasopressors

Measure: Hypotension Requiring Vasopressors

Time: 90 Days


No related HPO nodes (Using clinical trials)